Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (16)

2024

  1. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

2022

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

  2. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

    Ophthalmology Retina, Vol. 6, Núm. 11, pp. 1044-1053

2021

  1. Recommendations for ophthalmologic practice during the easing of COVID-19 control measures

    Acta Ophthalmologica, Vol. 99, Núm. 7, pp. e973-e983

  2. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study

    Acta ophthalmologica, Vol. 99, Núm. 8, pp. 861-870

2020

  1. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study

    Acta Ophthalmologica, Vol. 98, Núm. 7, pp. e820-e829

2018

  1. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration

    Acta Ophthalmologica, Vol. 96, Núm. 2, pp. e201-e212

  2. Clinical decision-making when treating diabetic macular edema patients with dexamethasone intravitreal implants

    Ophthalmologica, Vol. 240, Núm. 2, pp. 61-72

2017

  1. Prevalence of Vitreoretinal Interface Abnormalities on Spectral-Domain OCT in Healthy Participants over 45 Years of Age

    Ophthalmology Retina

2015

  1. Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration

    Current Opinion in Ophthalmology, Vol. 26, Núm. 3, pp. 200-205

  2. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

  3. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

    Drugs and Aging, Vol. 32, Núm. 10, pp. 797-807

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014

  2. Evaluation of macular retinal ganglion cell-inner plexiform layer thickness after vitrectomy with internal limiting membrane peeling for idiopathic macular holes

    BioMed Research International, Vol. 2014

2011

  1. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy

    Nature Genetics

2008

  1. Staphylococcus spp. en España: Situación actual y evolución de la resistencia a antimicrobianos (1986-2006)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 5, pp. 269-277